Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers
AssigneeConstellation Pharmaceuticals, Inc.
InventorsWilliam D. Bradley, Jike Cui, Kaiming Sun, Patrick Trojer, Jing Wang, Rentian Wu
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3- yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.
Claims11
A method of treating a prostate cancer in a subject, wherein the prostate cancer comprises at least one pathogenic androgen receptor mutation, said method comprising administering to the subject an effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound having the formula:
- or a pharmaceutically acceptable salt thereof;
- and an effective amount of an androgen receptor signaling inhibitor.
Dependencies are inferred from the claim text.